[Advances in the management of renal cell carcinoma].
Renal cell carcinoma accounts for about 3-4% of all malignancies and its incidence is steadily rising. The article presents in short the rationale behind the targeted therapies and provides an update on current therapeutic approaches to metastatic renal cell carcinoma. It also summarizes the most recent developments in the immunotherapy such as immune checkpoint inhibitors, anti-cancer vaccines and chimeric antigen receptors on T cells.